Our goal is to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcome.

Our lab currently studies hypoxia, prolyl hydroxylase, and VHL signaling in cancer, especially breast and renal cell carcinomas.